A prior study from our institution suggested that SMAD4 loss correlates with an adverse outcome in patients with locally advanced pancreatic cancer receiving gemcitabine, oxaliplatin and cetuximab [24]. This evidence concerns the gene SMAD4 and pancreatic neoplasm.